POTS Rarely Travels Alone
Hypermobile EDS, MCAS, ME/CFS, small fibre neuropathy, and post-COVID syndromes all share significant clinical overlap with POTS. Coordinated assessment matters.
You do not need a referral from your doctor. Request an appointment online in about two minutes, and we will call you to arrange a time. Testing takes 40–60 minutes.
Request an appointment →Please note the tests themselves are not covered by a Medicare rebate. Questions? Call 02 9388 0615.
The Overlap Is Real — and Large
One of the most clinically important things to understand about POTS is that it almost never exists in isolation. In the typical patient referred to us, you'll find multiple overlapping conditions — each contributing to overall symptom burden, each requiring its own management approach, and each often misdiagnosed in isolation.
Hypermobile Ehlers-Danlos Syndrome (hEDS)
The connective tissue connection
Hypermobile EDS is a connective tissue disorder characterised by generalised joint hypermobility, skin involvement, and a wide range of systemic features. The shared mechanism with POTS is thought to involve abnormal connective tissue around blood vessels — leading to excessive vascular distensibility, increased blood pooling in dependent areas, and exaggerated heart rate response to standing.
Common features Generalised joint hypermobility, recurrent joint dislocations or subluxations, soft stretchy skin, easy bruising, chronic musculoskeletal pain, gastrointestinal motility issues, anxiety.
Diagnosis hEDS is a clinical diagnosis — there is no confirmed gene for it, so no blood or genetic test can diagnose it. Assessment uses internationally recognised, evidence-based, expert-approved criteria: generalised joint hypermobility plus systemic involvement, with other EDS types and connective tissue disorders excluded. Often by clinical geneticist or experienced rheumatologist.
Why it matters for POTS hEDS patients with POTS often have more severe orthostatic intolerance, higher symptom burden, and need higher volume support. Physiotherapy needs to be POTS-aware (no rapid postural rehabilitation programmes).
Objective assessment If hypermobility may be part of your picture, a specialist hypermobility assessment can clarify it and send a structured report to your GP — see hypermobiletest.com.au, part of Autonomics Australia.
Mast Cell Activation Syndrome (MCAS)
The histamine and chemical mediator connection
MCAS describes inappropriate release of mast cell mediators (histamine, tryptase, leukotrienes, prostaglandins) producing recurrent multi-system symptoms. The overlap with POTS is striking — many POTS symptoms (flushing, palpitations, brain fog, GI dysmotility, urticaria) are also classical MCAS symptoms.
Common features Flushing, urticaria, dermatographism, sudden-onset GI symptoms (cramping, diarrhoea, nausea), anaphylactoid reactions to triggers, sensitivity to multiple foods/medications/scents, brain fog.
Diagnosis Clinically suggestive symptoms + response to mast cell stabilising treatment (e.g. H1 and H2 antihistamines, cromolyn, montelukast) ± biomarkers (tryptase, urinary N-methylhistamine, prostaglandin metabolites) — though biomarkers are often normal between episodes.
Why it matters for POTS Treating concurrent MCAS often improves POTS symptoms substantially. Patients who fail standard POTS treatment, particularly with prominent flushing or food sensitivity, deserve MCAS workup.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)
The post-exertional malaise connection
ME/CFS shares POTS's profound fatigue, brain fog, and orthostatic intolerance — and many POTS patients meet ME/CFS criteria. The defining feature of ME/CFS is post-exertional malaise (PEM) — disproportionate worsening of symptoms 12–48 hours after physical, cognitive, or emotional exertion, lasting days or longer. This pattern matters because conventional exercise rehabilitation can make ME/CFS worse.
Common features Substantial functional impairment, post-exertional malaise, unrefreshing sleep, cognitive impairment, orthostatic intolerance (POTS or orthostatic hypotension), often multi-system symptoms.
Diagnosis 2015 Institute of Medicine criteria (IOM) or Canadian Consensus Criteria. Clinical diagnosis after exclusion of alternatives.
Why it matters for POTS Patients with POTS+ME/CFS need pacing, not graded exercise. POTS-specific recumbent exercise protocols (Levine, CHOP) are designed for this — slow, recumbent or seated start, very gradual progression, with awareness of post-exertional crashes.
Small Fibre Neuropathy
The autonomic nerve connection
Around half of POTS patients have objective evidence of small fibre neuropathy — damage to the small unmyelinated nerve fibres that mediate pain, temperature, and autonomic function. This is the direct nerve damage that underlies neuropathic POTS (one of the major subtypes — see POTS subtypes).
Common features Burning or tingling feet, "walking on pebbles", patchy reduced sensation, autonomic features (sweating, GI motility, urinary). Pain often worse at night.
Diagnosis SudoScan, QSART, autonomic battery, skin biopsy with epidermal nerve fibre density count.
Why it matters for POTS Confirms the autonomic damage is objectively measurable. Changes the differential for cause (autoimmune, post-viral, diabetes, B12, idiopathic) and may unlock specific treatments where an autoimmune cause is identified.
Post-COVID Dysautonomia
The Long COVID connection
Post-COVID syndrome has substantially overlapped with the POTS / dysautonomia population since 2020. Many patients with Long COVID meet POTS criteria on autonomic testing, and the post-viral pattern is consistent with how POTS classically begins. Many also develop features of MCAS, ME/CFS, and small fibre neuropathy.
Common features Post-viral onset (4+ weeks after acute COVID), profound fatigue, orthostatic intolerance, brain fog, post-exertional malaise, varied autonomic symptoms (HR variability, temperature regulation, GI).
Diagnosis Diagnosis combines POTS criteria + clinical pattern consistent with post-acute COVID. NASA Lean test is often used as initial screen.
Why it matters for POTS Most established POTS treatments apply, with careful pacing for the ME/CFS overlap. Many patients improve over 12–24 months.
Why Coordinated Assessment Matters
One-stop autonomic + overlap workup
A comprehensive autonomic battery at our Sydney clinic identifies POTS, its subtype, and screens for small fibre neuropathy in the same visit. From there we coordinate as needed — clinical geneticist or rheumatologist for hEDS, immunology/allergy for MCAS workup, post-COVID services or sleep medicine where indicated. The key benefit: a single experienced clinician integrating the picture, rather than fragmented assessments missing the overlap.
A note on "trifecta" labelling
The "POTS-MCAS-hEDS" triad is real and important, but not every POTS patient has all three. Care should be taken not to label patients with conditions they do not actually meet criteria for — overdiagnosis is as much a problem as underdiagnosis. The right approach: assess what's actually present using established criteria, treat what's there.
Comprehensive POTS + Overlap Assessment
Single-visit autonomic battery + coordinated referral pathways for hEDS, MCAS, ME/CFS where indicated.
Book POTS TestingBook Your POTS Test Today
Stop waiting years for answers. Fill out the form below and we'll contact you to schedule your appointment. Get tested and receive your results within one week.
Thank you for getting in touch!
One of our colleagues will get back to you shortly.
Have a great day!